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Abstract 
The purpose of this task force was to critically analyze nine non-criteria manifestations of APS to support their inclusion as 
APS classification criteria. The Task Force Members selected the non-criteria clinical manifestations according to 
their clinical relevance, that is, the patient-important outcome from clinician perspective. They included superficial vein 
thrombosis, thrombocytopenia, renal microangiopathy, heart valve disease, livedo reticularis, migraine, chorea, seizures and 
myelitis, which were reviewed by thisInternational Task Force collaboration, in addition to the seronegative APS (SN-APS). 
GRADE system was used to evaluate the quality of evidence of medical literature of each selected item. This critical appraisal 
exercise aimed to support the debate regarding theclinical picture of APS. We found that the overall GRADE analysis was 
very low for migraine and seizures, low for superficial venous thrombosis, thrombocytopenia, chorea, longitudinal myelitis 
and the so-called seronegative APS and moderate for APS nephropathy, heart valve lesions and livedo reticularis. The next 
step can be a critical redefinition of an APS gold standard, for instance derived from the APS ACTION registry that will 
include not only current APS patients but also those with antiphospholipid antibodies not meeting current classification 
criteria. 
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1. Introduction 
1.1. Panorama of APS clinical criteria and diagnosis challenges 
Antiphospholipid syndrome (APS) classification process is characterized by the presence of 
antiphospholipid antibodies (aPL), namely anticardiolipin antibodies (aCL), anti-beta 2 glycoprotein I 
(anti-b2GPI), or lupus anticoagulant (LA) associated with thrombosis of arteries or veins or the 
microcirculation and/or well defined obstetrical manifestations. However, to date there are no accepted 
criteria for diagnosis of this condition, although classification criteria tend to be used for definition and 
for diagnostic purposes. Current classification criteria for definite APS were established in a workshop, 
preceding the 11th International Congress on aPL in Sydney. These criteria derived from the Sapporo 
preliminary classification criteria for APS [1]. 
Several clinical manifestations associated with aPL are not included in the revised classification 
criteria [1]. Since the Congress in Sydney, a significant body of basic research and clinical studies on 
APS has appeared, bringing new data and an opportunity to revise clinical as well as laboratory 
manifestations. Considering these new data, the main goal of this task force was to examine the body of 
evidence related to the set of clinical manifestations that are not included in the current criteria and their 
association with aPL. 
In this context, the Antiphospholipid Antibodies Task Force on Clinical Manifestations was carried out 
from January to September, 2013 to examine data, the quality of evidence according to GRADE system 
and develop recommendations in order to carefully suggest a revision of the current classification 
criteria [2]. A workshop held in Rio de Janeiro at the 14th International Antiphospholipid Congress 
discussed the findings [3] and [4]. We examined all potential clinical criteria and selected the most 
relevant ones, we did not discuss the obstetrical manifestations, the future trends in treatment and the 
catastrophic APS which were evaluated by other groups [5], [6] and [7]. 
2. Objectives 
The objectives of this task force were: (1) to assess the patient-important outcomes that have been 
considered as non-criteria APS manifestations, and (2) to assess the body of evidence of each outcome to 
support the recommendation to be included on APS classification criteria. 
3. Methodology 
The PICO question was formulated as: “In patients with APS (P), are non-criteria APS manifestations (I) 
associated with APS classification, leading to earlier and most adequate treatment intervention to improve 
the patient-important outcomes (O)”? 
We aimed to define and assess the outcomes that may be related to each non-criteria manifestation. An 
international group of APS experts of different specialties suggested non-criteria APS manifestations that 
were considered relevant. Some of the authors presented the current evidence in their area of expertise. 
Finally, during the Meeting, there was a debate in order to evaluate the proposal to include each 
manifestation as part of updated APS classification criteria. 
The outcomes were selected from the disease perspective. The importance of the outcome was evaluated 
according to its consequence to clinical decision-making (patient-important outcome). We considered the 
following: (1) the occurrence of this outcome on the disease in question and (2) the influence that it has to 
change the clinical care plan [8]. 
The categories were: critical for decision making (when it indicates risk of mortality), very important, but 
not critical for decision-making (when it indicates risk of disabilities, but no risk of death) and low 
importance for decision making (when it indicates transitory and slight discomfort to the patient). We 
have elaborated one PICO for each outcome. 
We followed three steps in considering the relative importance of outcomes: (1) preliminary classification 
of outcomes, before reviewing the evidence; (2) reassessment of the relative importance of outcomes after 
reviewing the evidence; and (3) judgment of the balance between the desirable and undesirable 
intervention effects. 
After the outcomes were chosen and discussed, the quality of the body of evidence was evaluated and 
summarized. The quality evaluation was based on the study design and the presence of methodology 
limitations. The dimensions that covered the assessment of the limitations were risk of bias; indirectness 
of evidence; inconsistency of results; imprecision of results and publication bias. 
It is important to emphasize the ‘directness’ dimension and how it was assessed in this task force. 
Directness is defined by whether the populations included in the studies correspond to the population in 
focus for the decisions under debate or not. Such an evaluation is difficult and could not be assessed 
objectively by this task force. To limit this bias, we first defined the PICO of each manifestation. Then, 
we defined the outcome(s) measured for each manifestation and it's (their) relative importance for the 
patient, from a clinician's perspective. This categorization was based on the discussion developed during 
the meeting with all participants, combined with the quality of evidence (GRADE system) to support the 
assumption that they could be associated with APS classification. The next step was the analysis of the 
overall quality of evidence for the manifestations selected and their correlated outcomes. This step 
provided a consensus approach of the current knowledge regarding each manifestation, the gaps of 
evidence and the framework to provide the recommendations and further steps on future studies. The non-
criteria manifestations included in the debate were: superficial vein thrombosis, thrombocytopenia, 
nephropathy, heart valve disease, migraine, chorea, transverse myelitis and seizures, and we also 
discussed the so-called seronegative APS (SN-APS). The results below are related to the assessment of 
the quality of body of evidence for the outcomes linked to each non-criteria manifestation to map the 
current knowledge about them, including their gaps of the evidence. It will allow us to construct the 
assumptions for further studies of APS classification criteria revision. Two independent investigators 
have performed data abstraction and quality assessment, and compared their results. The quality of 
evidence obtained was assessed using the GRADE approach. 
4. Results 
4.1. Superficial vein thrombosis 
PICO specific question: “In patients with APS, is superficial vein thrombosis associated with recurrent 
events, and would this criterion lead to earlier and most adequate treatment intervention to prevent the 
occurrence of recurrent thrombotic events, including serious life threatening events”? 
PICO: P — APS; I/C — superficial vein thrombosis manifestations; O — the occurrence of recurrent 
thrombotic events, including serious life threatening event. 
4.1.1. Patient-important outcome 
Superficial vein thrombosis (SVT) is a common disease, characterized by a thrombotic process in a 
superficial vein. The incidence is higher than of deep-vein thrombosis (DVT) (1/1000). SVT shares many 
risk factors with DVT, but affects twice as many females and frequently occurs in varicose veins. About 
8% of the patients with SVT experience symptomatic thromboembolic complications within three 
months, still most individuals with isolated SVT (without concomitant DVT) are commonly treated with 
low dose anticoagulation for a short term. Risk factors for concomitant DVT are recent hospitalization, 
immobilization, autoimmune disorders, age older than 75 years, prior DVT, cancer and SVT in non-
varicose veins. Risk factors for the occurrence of complications are male gender, history of venous 
thrombo-embolism (VTE), cancer, SVT in non-varicose vein or involving the sapheno-femoral junction. 
Ultrasound assessment and exclusion of DVT is essential [9]. 
Considering all of these aspects and the scarcity of evidence regarding SVT and aPL/APS 
correlation, the ‘occurrence of serious thrombotic consequences from SVT’ was defined as an important 
but not critical outcome. This categorization was corroborated by its exclusion in the revised 
classification criteria. Due to the limited data available at that time, but also to avoid over-classification of 
other diseases as APS in particular Behçet's disease in which SVT and aPL may coexist. 
4.1.2. Findings 
There were three studies included: two cohort studies in aPL/APS patients and one clinical trial in the 
general population. The first cohort study investigated clinical and serological features in patients with 
APS. They found that SVT occurred in 9.1% of the patients with APS [10]. The second cohort explored 
the risk factors for thrombotic events after 35 months of follow-up in patients with aPL. Although 
seemingly benign, SVT predicted a 7.5-fold increased risk for incident thrombotic events in aPL patients. 
The univariate analysis showed that patients with both aPL and activated protein C resistance have an 
increased risk for thromboembolic events (hazard ratio [HR] 3.67 [95% confidence interval [CI] 1.31–
10.31]). The multivariate analysis found that SVT remained an independent risk factor (HR 7.45 [95% CI 
2.25–24.66]) for further thromboembolic events. 
As evidence supporting treatment of isolated SVT was sparse and of poor quality, the large, randomized, 
double-blind, placebo controlled (RCT) CALISTO trial was conducted in the general population 
assessing the effect of fondaparinux on symptomatic outcomes in isolated SVT [11]. This study showed 
that, compared to placebo, 2.5 mg fondaparinux given for 45 days reduced the risk of symptomatic 
thromboembolic complications by 85% without increasing bleeding. Based on CALISTO and other 
observational studies, evidence-based recommendations can be made for most SVT patients. Further 
studies can now be performed in higher risk patients including patients with aPL to address unresolved 
issues. 
4.1.3. Overall quality of evidence and recommendations 
The overall quality of evidence was GRADE high, at the start with two cohort studies and one RCT in the 
general population. However there were limitations, as the patients included in the RCT were not directly 
representative (general population), decreasing it to GRADE moderate. Additionally, there were few 
studies, making the recommendation support vulnerable, with risk of interpretation bias. Based on these 
studies, there is low quality of evidence that suggests that SVT can be included in APS classification. 
4.2. Thrombocytopenia 
Specific question: “In patients with APS (P), is thrombocytopenia (I) associated with APS classification, 
leading to earlier and most adequate treatment intervention to prevent the occurrence of recurrent 
thrombotic events and other complications including serious life threatening event (O)”? 
PICO: P — APS; I/C — thrombocytopenia; O — the occurrence of recurrent thrombotic events, and other 
complications including serious life threatening event. 
Patient-important outcome: occurrence of recurrent thrombotic events and other complications. 
Preliminary relative importance: critical for decision-making. 
4.2.1. Patient-important outcome 
Clinicians and researchers have shown that thrombocytopenia is frequent in APS (20 to 46%) but its 
paradoxical association with thrombosis is noteworthy. This information is relevant to practical decisions 
such as prevention of recurrent thrombosis and may guide treatment decisions. Additionally, the 
assumption that patients with thrombocytopenia and aPL are at high risk for developing APS contributes 
to considering this outcome (recurrent thrombotic events) as critical for decision making. 
4.2.2. Findings 
Eleven cohort studies were included. They investigated, respectively: the frequency of thrombocytopenia 
in APS patients; the frequency of aPL positivity in patients with thrombocytopenia; and the clinical 
importance of idiopathic thrombocytopenic purpura (ITP), and how positive aPL in patients with 
thrombocytopenia is clinically important for decision making. The patient-important outcome was the 
occurrence of recurrent thrombotic events and it was categorized as critical for decision-making. 
Several studies demonstrated a high prevalence of aPL in ITP patients and some explored its possible 
correlation with thrombosis [12]. Yang et al. performed an observational prospective study that aimed to 
determine the frequency and clinical implications of elevated aPL in adult patients with ITP. The authors 
identified aPL positivity in 28.5% of the patients in this ITP cohort [13]. 
Observing that some patients with ITP paradoxically had an increased risk of thrombosis when 
therapeutic interventions corrected thrombocytopenia Kim et al. conducted a retrospective study that 
investigated the prevalence and clinical significance of aPL in ITP patients and assessed the risk factors 
for thrombosis. They found aPL in 41.6% of 165 patients with ITP; patients with aPL had an increased 
incidence of thrombosis (21.7% vs. 6.2%), LA and hypertension were independent predictors of 
thrombosis [14]. Danasu et al. conducted a retrospective analysis that explored aPL positivity in patients 
with isolated thrombocytopenia and correlated this finding with the occurrence of thromboembolic (TE) 
events. Thrombosis was observed in 22% of 64 patients evaluated, 14% with aPL [15]. Diz-Küçükkaya et 
al. conducted a prospective cohort study where the prevalence and clinical significance of aPL were 
investigated in 82 patients with ITP. Eighty-two newly diagnosed ITP patients were prospectively 
studied. They were evaluated for the presence of LA and aCL IgG and M. Thirty-one patients (37.8%) 
had a positive aPL at diagnosis. After five years of follow-up, cumulative thrombosis-free survival of 
aPL-positive (n = 31) and aPL-negative (n = 51) ITP patients was 39% and 97.7%, respectively. A 
significant difference was found between these groups by log-rank test (p = 0.0004). LA was an important 
risk marker for the development of thrombosis in ITP patients. After an average follow-up of 38 months, 
14 ITP patients (45%) who had aPL positive developed clinical features (thrombosis or fetal losses) 
related to APS. There were no differences between the aPL-positive patients with and without APS 
regarding the initial platelet counts, response to therapy, or aCL positivity. LA was significantly more 
frequent in those with ITP who developed APS (p = 0.0036; relative risk [RR] 7.15; 95% CI 1.7–47) [16]. 
The exact frequency and clinical meaning of aPL in ITP patients is still unknown. A single center 
retrospective cohort assayed aCL, LA and anti-b2GP1 in 215 recently diagnosed ITP patients. Analyzing 
the risk factors for thrombosis, the multivariate analysis showed that thrombotic events were associated 
with age (HR 1.6; 95% CI 1.2–2.4), LA (HR 9.9; 95% CI 2.3–43.4) and high level IgG-aCL level (HR 
7.5; 95% CI 1.8–31.5). The meaning of this result is that all the patients with aPL who developed a 
thrombosis were less than 45 years of age whereas nine of the 10 patients without aPL who did have a 
thrombotic event were over 45 years of age (p = 0.005) [17]. In contrast, in another ITP study, aPL were 
found in 46.3% and after a relatively short follow-up period, individuals with elevated aPL neither 
showed nor had a history of thrombosis. Because of this finding, the latter authors do not support a role 
for aPL in the pathogenesis of ITP [18]. 
Since thrombocytopenia is an important feature of systemic lupus erythematosus (SLE), it is crucial to 
determine if it is also associated with primary APS (PAPS). The first report from the Italian aPL registry 
described that the prevalence of thrombocytopenia in patients with PAPS was similar to that seen in 
patients with SLE associated APS [19]. In 1997, Cuadrado et al. analyzed retrospectively the prevalence, 
clinical and serological associations of thrombocytopenia in 171 APS patients. Severe thrombocytopenia 
(< 50 × 109/L) was detected in six (17.6%) patients at some point during the follow-up period. Also, a 
higher percentage of SLE associated APS (55%) was found in the thrombocytopenic group. Both results 
were not statistically significant, and maybe limited by the small sample size [20]. 
Thrombocytopenia in PAPS is still a gray zone of evidence. In the Euro-Phospholipid Project, 
thrombocytopenia was found in 21% of PAPS patients. This project started in 1999 as a multicenter, 
consecutive and prospective designed trial. A total cohort of 1000 patients with APS, derived from 13 
countries, has been followed since then. Although thrombocytopenia was correlated to patients with APS 
associated with SLE, it was not correlated in patients with primary APS [16]. A prospective Serbian 
cohort study showed that thrombocytopenia was observed significantly more frequently in patients with 
secondary APS, when compared with primary APS group, which corroborates the findings from other 
studies [21]. 
Comellas-Kirkerup et al. retrospectively reviewed 187 consecutive, patients with primary APS from a 
tertiary care center. This registry included APS patients as well as patients with positive aPL and non-
criteria clinical manifestations. Fifty-five patients (44 women, 80%) had hematological manifestations. 
Thirty-five patients (64%) had thrombocytopenia, 14 (25%) had autoimmune hemolytic anemia and 6 
(11%) had Evan's syndrome. The authors analyzed the frequencies of LA in patients with or without 
definite APS with hematologic manifestation. They found that patients with thrombocytopenia, including 
two with Evan's syndrome, from the clinical APS group were 2-fold more frequently positive for LA 
(71%) than from the non-clinical APS group (35%; OR 4.46; 95% CI 1.11–17.90; p ≤ 0.05) [22]. Three 
hundred and seven APS patients were retrospectively evaluated by Krause et al., most patients had PAPS 
(n = 173, 56.1%) and in 104 patients APS was associated to SLE (33.9%); 90 patients had 
thrombocytopenia (29.3%). Thrombocytopenia was significantly more frequent in APS patients with SLE 
when compared to PAPS patients (41.9% vs. 23.1%, p = 0.001). Significant associations were found 
between thrombocytopenia and cardiac valves thickening and dysfunction, epilepsy, chorea, arthritis, 
livedo reticularis and skin ulcerations. In contrast, the rates of thrombotic episodes as well as obstetric 
complications were similar in patients with and without thrombocytopenia. These data suggest that 
thrombocytopenia may be a risk factor for cardiac, neurological and cutaneous manifestations in APS 
patients [23]. Currently, an ongoing International Clinical Database of aPL-positive patients (APS 
ACTION) is enrolling at least 1000 patients to be followed over 10 years. Non-criteria aPL related 
manifestations such as thrombocytopenia will be investigated [24] and [25]. 
4.2.3. Overall quality of evidence and recommendations 
For the clinical practice, considering the body of evidence, it starts as GRADE moderate as one study had 
patients with other diseases included. Relevant cohorts were included, most of all with large follow-up, 
substantial sample size (in view of the low prevalence of the disease), with an elegant methodology 
(defined by the checklist of the critical appraisal methodology) and robust magnitude of effect, translated 
by the statistically significant and clinically meaningful findings. One study included a small sample size 
of several subgroups whose results were imprecise, and another study with short follow-up and with no 
correlation to any important outcomes. The final evaluation was GRADE low. The evidences have shown 
that thrombocytopenia does not reduce the risk of further thrombosis. 
These evidence support a suggestion that thrombocytopenia should be considered as a classification 
criterion of APS. Further research shall be conducted in order to better understand these findings and 
therapeutic consequences. 
4.3. Renal microangiopathy 
Specific question: “In patients with APS (P), is APS Nephropathy (APSN), defined by thrombotic 
microangiopathy (TMA), associated with APS classification (I), leading to earlier and most adequate 
treatment intervention to prevent the occurrence of kidney failure or death from kidney failure (O)”? 
PICO: P — APS; I/C — APS Nephropathy (APSN), defined by thrombotic microangiopathy (TMA); O 
— kidney failure or death from kidney failure. 
Patient-important outcome: kidney failure or death from kidney failure. 
Preliminary relative importance: critical for decision-making. 
4.3.1. Patient-important outcome 
The kidney is currently recognized as a major target organ in both PAPS and SLE-related APS. The 
outcome of interest here is kidney failure or death due to kidney failure. APS nephropathy (APSN), 
defined by thrombotic microangiopathy (TMA), characterized by fibrin thrombi in glomeruli and/or 
arterioles, has been the most frequently reported intra-renal vascular lesion in aPL-positive patients with 
or without lupus. Additionally, from a clinical perspective, renal manifestations have in common between 
SLE and APS the high prevalence of systemic hypertension and proteinuria. Although these diseases may 
have other clinical presentations, they can be superimposed. From a clinical practice point of view, the 
clear definition of whether such a renal presentation is related to SLE or APS will determine distinct 
treatment decisions. Taking this into account, kidney failure and/or death by kidney failure was defined as 
very critical outcomes. 
For the assessment of the dimensions that determine the quality of evidence, we might question in the 
first place how closely APSN is correlated with the patient-important outcome that would lead to decision 
changes in order to improve it. If the evidence points toward a close relationship between APSN and 
patient-important outcomes (here, kidney failure and/or death by kidney failure), then the quality of 
evidence should not decrease. TMA seems to be the surrogate marker of interest for the patient-important 
outcome that precedes APSN and should be used as the surrogate and the relationship between TMA and 
kidney failure — the outcome we want to address. So, the question is if either APSN or perhaps TMA is 
correlated with patient important outcomes and how likely it is that it progresses to disease [26]. This 
reasoning guided the judgment of the quality of the body of evidence. 
4.3.2. Findings 
To quantitatively support this judgment, we looked at the findings from the previous task force [27]: 
among primary APS patients with renal involvement, APSN was observed in 100% of cases in almost all 
considered studies. Summary data from all the studies that examined patients with positive aPL (with or 
without APS) in comparison with those without aPL showed a higher frequency of APS nephropathy in 
those patients with circulating aPL (p < 0.001). 
Most renal lesions in APS have been described as intra renal thromboses, but there remains a lot to be 
learned concerning the spectrum of APSN: the frequency, severity, symptomatology, and even the basic 
histology of these lesions. 
To support the assumption that TMA can be the surrogate of interest for the patient-important outcome 
that precedes APSN, animal/in vitro studies were included in this analysis. Nangaku et al. presented 
consistent results that confirm earlier studies, which establish a significant protective role for CD59 in 
modulating immune glomerular injury in vivo. They extended their observations by localizing the effect 
to the GEN in the model they described of immune TMA induced by the renal artery perfusion of anti-
glomerular endothelial cell (anti-GEN) antibody. These findings support the hypothesis that modulation 
of CD59 activity may have important benefits in multiple diseases in which anti-endothelial antibodies 
may be pathogenic [28]. Using different mouse monoclonal and human aPL antibodies, Seshan et al. 
developed an original animal model of renal injury that shares many features with TMA. They described 
more than one mechanism/signaling pathway involved in glomerular injury induced by aPL antibodies. 
Both complement-dependent and -independent pathways were identified to induce glomerular endothelial 
cell damage and renal function impairment [29]. While theories can be constructed around any possible 
mechanism, a theory is only as good and informative as the data that support it (and from which it may be 
derived). Considering this, these findings together build the hypothesis for the valid clinical diagnostic 
studies that may provide the contextual link of whether or not these theories were confirmed. 
Several studies have been corroborating the assumption that TMA is a surrogate for APSN and, 
consequently, for kidney failure by APSN. In a recent long follow-up study examining the significance of 
the inclusion of renal vascular lesions in the ISN/RPS classification system for lupus nephritis, TMA was 
associated with the poorest outcome regarding the five and ten year renal survival [30]. The findings 
presented by this study add to the current knowledge the notion that the renal lesions in the series are 
representative of those seen in PAPS and are correlated to high titer aCL. TMA can be a relevant outcome 
to be measured in future studies from different perspectives. 
For this review, six papers were included; the in vitro studies presented above were not included on 
GRADE analysis, but they corroborate this construct. The main questions were which clinical and 
histopathological lesions can be found in renal biopsy that define a morphologic picture suggestive of 
APS and its implication on clinical decision-making. 
Amigo et al. found renal disease in 25% of the 20 patients with PAPS evaluated at a cross-sectional study 
whose dimension of directness for the question addressed in this outcome was contemplated. It is 
justified, as only APS patients were included, carefully excluding SLE from the sample. TMA — the 
surrogate marker of the outcome evaluated here — was investigated in those with definite APS 
classification with renal clinical findings (proteinuria, hypertension and renal failure). There are some 
limitations of this pioneer study that reduces the quality of evidence on the context of the body of 
evidence for this task force. On the other hand, biopsy findings were consistent with a TMA involving 
both arterioles and glomerular capillaries. These demonstrations would reduce the presence of some 
plausible residual confounding, which would suggest a spurious effect if no effect was observed [31]. 
In 1999, Nochy et al. retrospectively examined the kidney biopsies of 16 patients with PAPS in a 
multicenter cohort study and followed-up for five years or more. This group explored the clinical and 
histopathologic lesions on renal biopsies, which define a morphologic picture that should suggest the 
diagnosis of APS. All 16 patients had positive tests for LA, aCL or both. In all cases of PAPS, there was a 
vascular nephropathy characterized by small vessel vaso-occlusive lesions associated with fibrous intimal 
hyperplasia of interlobular arteries (12 patients), recanalizing thrombi in arteries and arterioles (six 
patients), and focal cortical atrophy (ten patients). They also described extra renal manifestations related 
to thrombosis and that they were likely to be correlated to high aCL levels (62% of patients > 40 GPL 
units), linked to the severity of the thrombotic process. Moreover, the extra-renal clinical involvement in 
these patients corresponded to that described in PAPS. Although this small sample may provide 
inconsistent and imprecise results, the ensemble of histologic renal lesions defined in this study should 
aid in the separation of the lesions found in cases of secondary APS, especially SLE, into those lesions 
related to APS. This information contributes to support decisions on clinical practice, despite these 
limitations [32]. 
Defining the nature of renal disease in lupus in the context of APS represents a challenge to practitioners 
and Daugas et al. investigated whether the renal histopathologic lesions of APS could be as accurate as N-
SLE to discriminate the nature of the nephropathy in patients with SLE-APS. To address this question, 
they performed a second retrospective cohort study to determine: (1) if APSN as the group have described 
on the previous study could be found in the most frequent secondary form of APS, associated with SLE; 
(2) if some patients with SLE have risk factors associated to the development of an APSN; and (3) if 
APSN is a superadded renal morbidity factor in lupus patients. They included 114 patients that divided in 
seven groups of patients according to clinical, obstetrical and laboratory criteria. They found that APSN 
in SLE is independent of the class of lupus glomerulopathy. Thirty-six patients (32%) presented one or 
more histologic lesions of APSN: 20 patients (18%) had acute lesions of APSN, of whom nine patients 
had acute APSN alone, four patients with acute APSN and fibrous occlusion and ischemic cortical 
atrophy (FCA); 27 patients (24%) had chronic lesions of APSN, of whom 17 (15%) had associated FCA; 
eleven patients had both acute and chronic APSN. In none of the patients in whom it was identified FCA 
as the exclusive lesion suggestive of APSN. For accuracy studies, wide confidence intervals for estimates 
of test accuracy or true and false positive and negative rates can reduce quality of evidence (imprecise 
evidence dimension). In this study, statistical tests revealed significant associations between the presence 
of APS or a positive test for LA and the existence of an APSN (OR 6 and 5.9, respectively; p = 0.0001 for 
both), a chronic APSN (OR 3.8, p = 0.005 and OR = 5.7, p = 0.0001, respectively), an acute APSN (OR 
3.7, p = 0.026 and OR 3.8, p = 0.007, respectively), or FCA lesions (OR 9.2, p = 0.0002 and OR 
8.2, p = 0.0001, respectively). However, in contrast with LA, aCL showed no significant association with 
APSN, chronic APSN, acute APSN, or FCA lesions, no matter the aCL titer (median, 28 GPL units [0–
760] for patients with APSN compared with 23 GPL units [0–178] for patients without APSN [p = 0.77]). 
Only three patients (15%) with neither aCL nor LA (non-aPL group) showed APSN, giving a negative 
predictive value of 85% for aCL and LA in predicting APSN. In conclusion, these data illustrate that 
limitations due to imprecision and inconsistencies were absent [33]. We could not find limitations in this 
study and it is important to emphasize that its relevance is not only because it established the existence of 
APSN within SLE, but it has also shown that these lesions belong to the group of APS-related vascular 
manifestations independent of SLE. Its presence in conjunction with lupus nephropathy probably 
increases the risk of evolution toward end-stage renal disease. This information may contribute to define 
clinical practice decisions. 
Tektonidou et al. explored a further understanding about the clinical and laboratory associations in 
patients with SLE associated with APSN [34]. Additionally, this team examined the frequency of APSN 
in patients with SLE. APS nephropathy was diagnosed in 32 (39.5%) of 81 SLE patients with aPL, 
compared with only three (4.3%) of the 70 SLE patients without aPL (p = 0.01). The prevalence of APSN 
in SLE patients with secondary APS and in SLE/non-APS patients with aPL was 67% and 31.7%, 
respectively. A strong association between APS nephropathy and APS, LA [OR 11.46 (CI 95% 3.1–
41.7)], aCL [OR 5.7 (CI 1.8–17.8)], and hypertension [OR 4.0 (CI 1.5–8.6)] was noted. Odds ratio (OR) 
calculations were based on the risks of APSN, given the absence or presence of the clinical and laboratory 
findings. These findings also corroborate the initial studies by Glueck [35] and Kant [36], which found 
that TMA in renal biopsies of SLE patients was associated with LA and thrombotic events. 
Later, the same group (2008) examined the renal histological, clinical and laboratory characteristics of 
different groups of patients with APS including catastrophic APS (CAPS)[37]. The study included CAPS 
(n = 6), PAPS (n = 8), and SLE-APS (n = 23) patients with biopsy-proven renal involvement. Regarding 
PAPS and SLE-related APS patients, TMA was detected in 37.5% and 35% of patients, respectively, 
while the frequencies of FIH and FCA were similar to those observed in CAPS patients (p > 0.99). This 
was the first time that the renal histologic, clinical, and laboratory characteristics of three different groups 
of APS patients with biopsy-proven renal involvement was compared the pertinent data. The most 
frequent findings in all three APS groups were hypertension, proteinuria, hematuria, and renal 
insufficiency. The presence of the same characteristics of APSN among all three groups of APS patients 
suggests an association between this nephropathy and APS. According to these authors, APSN should be 
included in the classification criteria for definite APS, and the use of an appropriate treatment in these 
patients should be examined. However, for a better understanding of the TMA role in patients with SLE, 
the renal SLE outlook was assessed by Song et al. They explored the clinical, laboratory and pathological 
features as well as risk factors for clinical outcomes of patients with TMA in lupus nephritis [38]. They 
presented a detailed histopathological analysis of a series of 148 patients with biopsy-proven lupus 
nephritis, focusing on the prevalence of TMA and found such lesions in 36 out of the 148 patients with 
lupus nephritis. Although it is indirect, which decreases the overall quality of evidence, this study 
corroborates the knowledge that patients with SLE can develop other kidney disorders that may be related 
or not to SLE. 
4.3.3. Overall quality of evidence and recommendations 
The critical appraisal of these studies shows that their methodologies have several strengths that draw our 
attention. First, the studies' designs are appropriate for valid diagnostic studies. On average, patients have 
clear recruitment criteria and address clear-cut PAPS. They all meet the classification criteria for PAPS; 
some studies included APS versus SLE comparison. Additionally, one study that is focused on SLE was 
included on this analysis as it corroborates the body of evidence. 
When it comes to assessment limitation, the judgment regarding the presence of indirectness in this last 
study represented the greatest challenge for this workgroup. APSN is closely correlated with kidney 
failure — the patient-important outcome in focus. TMA is assumed as a surrogate of interest for the 
patient important outcome that precedes APSN. Also, aPL profile is assumed as a surrogate of the disease 
in question, that is APS. Overall GRADE started as high and decreased to moderate because of this. As it 
is a very critical important outcome whose definition will imply in intervention that will change the 
outcome, we assumed that this indirectness of sample selection (SLE) addresses the questions for this 
patient-important outcome; it decreases even more the overall quality of evidence. 
Therefore, there are bodies of evidence with moderate quality to support a recommendation that APSN 
should be included in the APS classification. Additionally, gaps of knowledge were identified suggesting 
that future research directions need to include prospective multicenter studies that analyze APSN 
histological criteria. Large-scale studies will be relevant for the identification of the characteristics of 
APSN associated with worse renal prognosis. The effect of anticoagulation or targeted treatments (to C5a, 
for example) on long-term outcome of APSN should also be examined in prospective randomized studies. 
4.4. Heart valve disease 
Specific question: “In patients with APS, are heart valve lesions defined by (a) valve thickness > 3 mm; 
(b) localized thickening involving the proximal or middle portion of the leaflets; or (c) irregular nodules 
on the atrial face of the mitral valve and/or the vascular face of the aortic valve associated with APS 
classification (I), leading to earlier and most adequate treatment intervention to prevent the occurrence of 
heart failure, valve replacement or death from heart failure/valve replacement”? 
PICO: P — APS; I/C — valve lesions defined by (a) valve thickness > 3 mm; (b) localized thickening 
involving the proximal or middle portion of the leaflets; or (c) irregular nodules on the atrial face of the 
mitral valve and/or the vascular face of the aortic valve; O — heart failure, valve replacement or death 
from heart failure/valve replacement. 
4.4.1. Patient-important outcome 
According to the editorial published by Petri M, using these strict requirements for evidence-based 
criteria, cardiac valvular disease (thickening or vegetations) should clearly be included in APS criteria. 
Multiple supportive prospective cohort studies and case–control studies, were presented which 
corroborate the existence of a strong pathophysiologic rationale for considering cardiac valve disease as a 
manifestation of APS [39]. Positive associations have been found using both study designs and in both 
SLE and non-SLE populations, meeting the criteria for inclusion in evidence-based classification criteria. 
With the emphasis, however, that it is necessary for valvular disease to be stringently defined as valve 
thickening or valve vegetations [40]. 
In the context of APS, valve lesions are defined by (a) valve thickness > 3 mm; (b) localized thickening 
involving the proximal or middle portion of the leaflets; or (c) irregular nodules on the atrial face of the 
mitral valve and/or the vascular face of the aortic valve. Its consequence in clinical practice is heart 
failure, valve replacement or death from heart failure. 
From the disease perspective, it is crucial to identify whether heart valve disease is present or not, as it 
will imply aggressive treatment care plan [41]. The patient-important outcome from the clinical 
perspective is heart failure, heart valve replacement or death from heart failure/valve replacement and 
these outcomes are categorized as very critical for decision-making. To illustrate this importance on 
clinical practice, a case report of a 49 year-old woman with a history of rheumatic fever at 14 years of age 
described by Espinola-Zavaleta is presented here. At 49, a yearly routine two-dimensional transthoracic 
and transesophageal examinations and three-dimensional reconstruction were performed, which made it 
possible to dismiss a rheumatic etiology for the valve lesions, as large nodules were found on the free 
edges of both mitral leaflets without thickening or fusion of the subvalvular apparatus. Because of the 
echocardiographic evidence of probable PAPS, an immunological profile was performed. Findings 
included negative rheumatoid factor, negative antinuclear antibodies and negative aCL with strong 
positive anti-b2GP1 and false positive VDRL [42]. This case is interesting as it involves a woman who 
suffered her first episode of rheumatic fever at the age of 14 years. It was the echocardiogram that first 
suggested an autoimmune disease and specifically APS because nodules were found on the free borders 
of both mitral leaflets and aortic valve leaflets without evidence of thickening or fusion of the subvalvular 
apparatus. The diagnosis of PAPS was confirmed by identifying antibodies against b2GP1 in the clinical 
evidence of SLE. This case report calls for attention for the consequences of misdiagnosis for the patients 
and for the potential role of echocardiographic and immunologic tests in establishing the diagnosis of 
APS with valve lesion and making it possible to distinguish it from rheumatic heart disease. 
4.4.2. Findings 
Ten studies were included in this analysis, of which two are case–control studies, two cross-sectionals, 
three cohorts, one randomized clinical trial and two systematic reviews. The main research questions 
regarded the clinical and serological features in long-term of cardiac manifestations in patients with APS; 
the frequency; how to identify it with accuracy, in order to discriminate APS-related heart valve disease 
of rheumatic and infectious heart valve disease; which clinical associations could be expected and the risk 
factors that were involved. The outcome measurements were, respectively, clinical questionnaires; 
echocardiography; and SPECT study (myocardial perfusion) Additionally, there were studies that 
analyzed antinuclear antibodies, serum levels of aCL and anti-b2GP1 antibodies (IgG and IgM) 
measurements for correlations analysis. 
A case–control study published in 1996 described the prevalence and clinical significance of aPL in heart 
valve disease in order to determine whether the presence of aPL antibodies carries an increased risk for 
thrombotic events [43]. Eighty-nine consecutive patients and 80-matched control subjects were tested for 
IgG and IgM aCL and for LA. The prevalence of aPL antibodies was significantly higher in patients (19 
[21%] of 89) than in controls (7 [9%] of 80; p < 0.05). Patients were divided into two subgroups 
according to the presence (A) or the absence (B) of aPL antibodies. No significant difference in age or 
gender ratio was observed between the two subgroups. A history of arterial thrombosis was more frequent 
in Group A (8 [42%] of 19) than in B (8 [11%] of 70) (p < 0.01). No significant difference with respect to 
the occurrence of thrombotic events was observed during an average follow-up period of 8.7 months. 
Thus, a high prevalence of aPL antibodies was found in patients referred for heart valve replacement 
compared with matched controls. No increased risk has been demonstrated in the patients with aPL 
antibodies. 
The evolution of valve involvement and myocardial dysfunction over time in patients with SLE with or 
without aPL and/or APS was described on a 10-year cohort that included 17 patients with PAPS, 23 with 
SLE-associated APS (SLE/APS), 19 with SLE positive for aPL without APS, and 23 with SLE negative 
for aPL who were re-evaluated in the present echocardiography study [44]. Valvulopathy was measured 
by transthoracic echocardiography and it was detected in 65% of PAPS and 62% of SLE patients with or 
without aPL. Disease duration (OR 1.63; 95% CI 1.13–2.36; p = 0.009 for every five years of increase) 
and presence of SLE/APS (OR 3.51; 95% CI 1.27–9.67; p = 0.015) were the only factors associated with 
the progression of valvular disease by univariate and multivariate analyses. The consequence of 
valvulopathy to the patient (the importance of this outcome for the patient) was examined, showing that 
left ventricular diastolic dysfunction similarly progressed over time, with deceleration time (DT) and 
isovolumetric relaxation time (IVRT) being equally prolonged in the four groups (p < 0.05). Right 
ventricular DT was significantly prolonged in all three SLE patient groups (p < 0.001), whereas IVRT 
increased only in SLE/APS patients (p = 0.040). 
The Serbian National Cohort study started in 2000 and analyzed cardiac manifestations in 374 patients 
(260 PAPS patients and 114 SLE/APS) during 10 years of follow-up [45]. The outcomes measured were 
aPL profile and cardiac manifestations, that were examined by echocardiography features. They found 
30.7% secondary APS patients and 9.2% PAPS patients with pseudo-infective endocarditis (p = 0.0001). 
Cardiac manifestations were observed in 28.7% of the patients who had more than one type of antibody, 
although it was not statistically significant (p = 0.78). Age was a significant factor for cardiac 
manifestations in APS (p = 0.001) and, finally, aCL IgG and IgM positivity was related to valvular 
changes in all APS patients and high aCL levels increased the risk of these manifestations. 
Clinical associations are also relevant for this topic. Krause that examined the association between cardiac 
and central nervous system, exploring cardiac valve disease; migraine (recurrent severe unilateral and 
bilateral headache); and epilepsy/seizures (simple partial, complex partial, or generalized tonic–clonic) 
using Doppler color flow echocardiographic and neurologic examinations [46]. The cardiac valve 
abnormalities in APS patients with cerebral vascular accident (CVA) were (for 284 sample): valve 
vegetation (p < 0.04); valvar thickening and dysfunction (p < 0.001) and for PAPS (n = 159) the 
abnormalities found were: valvar thickening and dysfunction (p < 0.03); and overall cardiac valve 
abnormalities (p < 0.02). A significant association was also found between all valvar lesions and stroke or 
transient ischemic attacks (TIA), although they found a borderline association between valvar vegetations 
and migraine (p = 0.09). 
Two 5-year transesophageal echocardiographic studies in primary APS demonstrated the progression of 
valve lesions and the ineffectiveness of oral anticoagulants and aspirin in terms of valvular lesion 
regression [47]. One of these prospective studies also investigated risk factors for the worsening or 
appearance of new valvular lesions over this 5-year follow-up. This study enrolled 56 APS patients. 
Before recruitment, 27 (48%) had had one or more episodes of arterial or venous thrombosis, 29 (52%) — 
recurrent thromboembolic events, and eleven (20%) had had just one fetal loss. Follow-up: three (5%) 
died; all had high aCL titers (> 40 GPL). High IgG aCL titers: 30 patients (54%) and high IgM aCL titers 
in 21 (38%). LA was detected in 47 patients (84%), and thrombocytopenia in 18 (32%). At baseline 
evaluation, TEE showed 64% of cardiac involvement (valvular thickening or vegetations and/or potential 
embolic sources) in 34 patients. Over the 5-year follow-up cardiac involvement was unchanged in 30 
subjects (64%). New cardiac abnormalities: 17 patients (36%), 15 (88%) with high IgG aCL and two 
(12%) with low IgG aCL titers. To corroborate the consistent and precise results, a multivariate logistic 
regression was carried out, evidencing that high IgG aCL represents the only independent risk factor for 
new and progressive cardiac abnormalities in APS patients [OR 4.5, 95% CI 1.70–15.05]. 
The accuracy of the measurement tool is also a research theme on the context of valve manifestation in 
APS, as it might have to discriminate to other conditions with implications for practical decision-making, 
as in the context of cardiac valve manifestation in SLE patients. Using a spectral Doppler, Amoroso et al. 
examined the prevalence of cardiac alterations detectable by transthoracic echocardiography (TTE) and 
the possible role of aPLs in determining heart damage [48]. The outcome in this study was valvular 
impairment, defined only when it was hemodynamically relevant. Thirty-four SLE patients and 34 
controls were analyzed. They observed that 19 (56%) SLE patients had at least one cardiac abnormality 
(p < 0.0001 — RR 19; OR 41.8; 95% CI 5.1–342). The predominant valve dysfunctions observed were 
mitral (21%) and tricuspid (18%) regurgitation, aortic regurgitation (12%), pericardial effusion (15%), 
and left atrial enlargement (12%). Echocardiographic abnormalities were more common in aPLs positive 
than in aPLs negative patients (69.6% vs 27.3%) (p = 0.02; RR 2.5; OR 6.1; 95% CI 1.2–30.1). LA was 
detected in 14 patients (44.1%) and negative in all controls (p < 0.0001). IgM and IgG aCL were present 
in eight (23.5%) and in 17 (50%) SLE patients, respectively, and were absent in the control group 
(p < 0.01). LA and/or aCL (low and medium-high titer) positivity was not significantly associated with 
the presence of TEE abnormalities. Anti-phosphatidic acid (aPA)-IgG antibodies were found positive in 
12 cases (35.3%) and were associated with left atrial enlargement (p = 0.01) and increased 
interventricular septum thickness (p < 0.05). The presence of anti-phosphatidyl serine (aPS)-IgG 
antibodies was detected in 14 cases (41.2%) and was associated with left atrial enlargement (p < 0.05). 
Anti-phosphatidyl inositol (aPI)-IgG antibodies, positive in 13 cases (38.2%), were statistically associated 
with left atrial enlargement (p = 0.01) and increased interventricular septum thickness (p < 0.05). IgM and 
IgG anti-b2GPI were present in six (17.6%) and in 12 SLE patients (35.3%), respectively, with no 
statistical association with echocardiographic findings. 
Continuing addressing the topic about the accuracy of tools to measure the valvulopathy as an outcome, a 
randomized controlled study conducted by Roldan et al. [49] analyzed the accuracy of TEE compared to 
the accuracy of transthoracic echocardiography (TTE) for detection of valvular heart disease and masses 
in SLE patients. They performed transesophageal echocardiograms in: (1) 54 patients with SLE, 22 of 
them with aPL (Group I) and 32 without aPL (Group II); (2) ten patients with APS (Group III); and (3) in 
35 normal individuals (Group IV). The patients in groups I and III had similar isotypes and concentrations 
of antibodies. LS vegetations were observed in 41% of the patients in Group I, 25% of II, 10% of III, and 
in no patient in IV (I or II vs. IV, p < 0.002). Valvular regurgitation was found in 64% of the patients in 
Group I, 59% of II, 10% of III, and in 20% of IV (I or II vs. III or IV, p < 0.006). This study demonstrated 
that in SLE, in the presence or absence of aPL, had similar prevalence and severity of valvular disease. 
Despite these results, it is suggested that the presence of aPL plays a role in the pathogenesis of the 
cardiac lesions in patients with SLE, as explored in two systematic reviews [50] and [51]. Mattos et al. 
carried out the first one in order to better understand this point in 2011. Twenty articles were found, 
which evaluated the association between the presence of aPL and valvulopathy. Thirteen of these studies 
evaluated the association of aPL with the LS lesion. Of the 20 articles, 15 demonstrated a positive 
association between aPL and valvular lesions, whereas five articles demonstrated that there was no 
association. Evidence of an association between the presence of aPL and valvular lesion was 
demonstrated in most of the studies. Nevertheless, the possible role of these antibodies in the 
etiopathogenesis of the heart valve lesion has not yet been proved. Zuily et al. conducted a systematic 
review and meta-analysis to estimate the risk for HVD and/or Libman–Sacks' endocarditis associated 
with aPL in SLE patients. They included 23 studies (15 cross-sectional, 7 cohort and one case–control) 
with 1656 SLE patients (668 with aPL, and 988 without aPL). HVD was present in 43% of aPL positive 
patients and in 22% of aPL negative patients. The OR for valvulopathy in aPL positive patients was 3.13 
(95% CI 2.3–4.24) and for Libman–Sacks' endocarditis 3.51 (95% CI 1.93–6.38). The risk of 
valvulopathy depending on aPL subtypes was the highest for LA at 5.88 (95% CI 2.92–11.84) and for 
aCL IgG at 5.63 (95% CI 3.53–8.97). Although they were SRs, for the purpose of this analysis, they were 
indirectness, as they analyzed patients with SLE, which down the GRADE. Despite this, they corroborate 
the assumption that aPL plays a role in the pathogenesis of the cardiac lesions in patients with APS. 
4.4.3. Overall quality of evidence and recommendations 
We found studies with robust design to address the issues included in this topic, including cohort studies, 
RCT and two systematic reviews that allowed us to start the analysis for the body of evidence as GRADE 
high. The frequency of the manifestation, clinical features in long term and consequence for clinical 
decision-making was explored in the studies analyzed. Some studies included SLE patients that aimed to 
discriminate its peculiarities in the context of APS, as it is categorized as critical for decision-making and 
will require different decisions for the practitioner. There is evidence that the prevalence of heart valve 
disease is very high in APS, the lesion according to definition is characteristic and even though the 
pathogenic mechanisms are not known, there is evidence that aPL have a role in these lesions. 
4.5. Livedo reticularis 
Specific question: “In patients with APS (P), is livedo reticularis, specifically livedo racemosa combined 
by positive aPL (I/C), associated with APS classification, leading to earlier and most adequate treatment 
intervention to prevent thrombotic events (O)”? 
PICO: P — APS; I/C — livedo reticularis, specifically livedo racemosa combined by positive aPL; O — 
the occurrence of recurrent thrombotic events, including serious life threatening event. 
4.5.1. Patient-important outcome 
Despite the fact that the dermatologic literature contains only reports of small series or isolated cases of 
cutaneous manifestations in APS, livedo reticularis has been considered as the most frequently observed 
dermatologic manifestation (25.5%), with a similar prevalence in PAPS (31%) and SLE-related APS 
(20%). It was a presenting manifestation in 17.5% of cases. Regardless of the type of skin involvement, it 
is important to remove or reduce other risk factors for thrombosis or arterial wall lesions. For example, 
patients are advised to stop smoking, and women are counseled against the use of estrogen-containing 
pills. The potential benefit of treatment with statins or angiotensin-converting enzyme inhibitors needs to 
be determined, especially in patients with livedo. With the assumption that livedo reticularis can be 
associated with thrombotic events, the patient-important outcome was defined as the occurrence of 
recurrent thrombotic events, including serious life threatening event. It was categorized as important but 
not critical for decision-making. 
4.5.2. Findings 
There were five studies and three were cohort studies. The outcome's classification of each study had 
directness in all of them. The patient-important outcome was the occurrence of recurrent thrombotic 
events, including serious life threatening events which were categorized as important but not critical for 
decision-making. 
Two studies evaluated the frequency of cutaneous lesions in patients with APS[52] and [53]. Diógenes 
included 21 patients with positive aPL profile without APS and found that 40% presented cutaneous 
features, of which 7% had livedo reticularis. Francès et al. showed a 49% frequency of dermatologic 
manifestation (livedo reticularis in 25%). Also, a decreased frequency of venous thrombosis was observed 
in patients with livedo reticularis (OR 0.2, 95% CI 0.1–0.5). Additionally of this research question, 
Francès et al. compared cutaneous manifestations with pregnancy morbidity, CNS and cardiac 
manifestation in order to investigate the risk to develop these manifestations. Significant livedo reticularis 
associations were verified in: (1) cerebral or ocular ischemic arterial events (OR 10.8, 95% CI 5.2–22.5); 
(2) seizures (OR 6.5, 95% CI 2.6–16); (3) all arterial events (OR 6.0, 95% CI 2.9–12.6); (4) heart valve 
abnormalities by TEE (OR 7.3, 95% CI 3.6–14.7); and (5) arterial systemic hypertension 
(> 160 × 90 mm Hg) (OR 2.9, 95% CI 1.5–5.7). Toubi et al. described livedo reticularis in 50 of 308 
patients with APS (16%) and also found significant associations between livedo reticularis and CVA 
(p = 0.01); migraines (p = 0.002); and epilepsy (p = 0.02) [54]. 
4.5.3. Overall quality of evidence and recommendations 
The overall quality of evidence to support the assumption that livedo reticularis — specifically livedo 
racemosa combined with positive aPL — is associated with APS classification in five cohorts started as 
GRADE high. However, in those that assessed frequencies, CI 95% and p-value were not shown, 
representing inconsistencies of results. These aspects decrease the quality of the body of evidence to 
GRADE moderate. Based on this, our recommendation reflects a belief that livedo reticularis should be 
evaluated in further studies to better support this assumption. 
4.6. Migraine 
Specific question: “In patients with APS (P), is migraine (I) associated with APS classification, leading to 
earlier and most adequate treatment intervention to preventthrombotic events (O)”? 
PICO: P — APS; I/C — migraine; O — thrombotic events. 
Patient-important outcome: thrombotic events. 
Preliminary relative importance: important but not critical for decision-making. 
4.6.1. Patient-important outcomes 
Migraine has been described as a common in patients with APS, and although it sometimes is responsive 
only to anticoagulants, any causal relation has not been proven. 
4.6.2. Findings 
Migraine has been described as a common symptom in patients with APS, and although it sometimes is 
responsive only to anticoagulants, the causal relation is an issue about which different groups of 
researches do not have a common opinion. With this conflict in mind a systematic review was performed. 
There were 10 studies included in this analysis. Among clinical features of 1.000 APS patients from 13 
European countries, 53.1% with PAPS, 36.2% with APS associated to SLE and 10.9% with APS 
associated with other diseases, migraine was mainly described on females — 23% vs. 12% [8]. These 
patients were followed for five years. Migraine was the most frequent neurologic manifestation, found in 
20.2% [20]. Krause et al. evaluated 246 APS patients, age ranging from 19 to 75 years old (61.8% PAPS). 
Migraine occurred in 19.5% of these patients [55]. In a retrospective analysis of 14 years, from 128 
patients with PAPS at first, Gómez-Puerta et al. observed who developed SLE or other autoimmune 
disease. The average age was 42 ± 12, with a follow-up of 9 ± 3 years. In the end, 86% of the patients 
remained with the PAPS diagnosis. Migraine was one of the main manifestations reported, encountered in 
40% of patients [56]. As presented in the cardiac section, Krause et al. (2005) also evaluated the 
connection between cardiac valvar lesion and CNS involvement in 284 APS patients (55.9% PAPS). 
Significant clusters were found between valvar vegetations and epilepsy (p < 0.002) and between valvar 
thickening/dysfunction — as well as overall valvar abnormalities (vegetations and/or valvar dysfunction) 
— and migraine (p = 0.002 for both). A borderline association was found between valve vegetation and 
migraine (p = 0.09). The migraine prevalence on the group as a whole was 18%, and this symptom was 
mostly found in the PAPS group (20.8% vs. 14.4%, respectively). 
Garcia-Carrasco et al. evaluated Latin American APS patients (57% PAPS, 35% APS associated with 
lupus, 8% APS associated with other diseases). Migraine was present in 25% of patients at the time of 
diagnosis [57], being the most frequent neurologic complaint. In comparison with the European Group, 
migraine was more frequent in the Latin Americans (OR 2.16, IC 95% 1.33–3.49, p = 0.001). 
A study including 100 Latin American Mestizos (from Colombia, Ecuador and Mexico), all fulfilling 
PAPS criteria, compared their clinical and immunological manifestations with 538 Caucasians with PAPS 
(from the Euro-phospholipid cohort). Migraine prevalence in both groups was 18%, and it was the most 
frequent neurologic complaint of the former [58]. 
As genetic factors may influence migraine development, Williams et al. evaluated the prevalence of aPL 
in migraine-discordant monozygotic twins. There was no statistically significant difference between the 
groups with or without migraine, or between patients of the migraine group as for the type of aPL 
present [59]. 
Cavestro et al. evaluated the prevalence of aPL in a random cohort of 284 migraine patients with or 
without aura, and compared them with 225 sex and age-matched controls. Positivity for at least one aPL 
test (LA, aCL IgG or anti-b2GPI IgG) was detected and confirmed in 33 (12%) patients and in 7 (3%) 
controls (OR 4.08; CI 1.77–9.39; p = 0.0004). The most prevalent antibody was anti-b2GPI IgG, present 
in 80.8% of patients and in 2.5% of controls (OR 3.51, CI 1.41–8.71, p = 0.004) [60]. 
The Serbian cohort previously cited (Stojanovich et al.) [19] analyzed 374 Caucasian patients, 69.5% 
PAPS, 30.5% APS associated with SLE. They investigated the association between non-criteria APS 
manifestations and aPL type and titers. They found migraine to be the most frequent complaint (70 
patients, 26.9%) in the PAPS group, occurring mainly in patients with IgM aCL (p = 0.017). The 
statistical analysis of the antibodies showed a connection between migraine occurrence and LA absence 
(p = 0.014). In APS associated with SLE, migraine was found in 32.5% of patients. 
4.6.3. Overall quality of evidence and recommendations 
Migraine is the most frequent CNS complaint in PAPS patients, and there is no association with a specific 
aPL. This feature is more prevalent among females, and it can be associated with cardiac vegetation. The 
literature does not show that this comorbidity is more prevalent in PAPS then in the general population. 
This limitation is due to the design of these studies (most of them are observational studies), and due to 
some (4/10) not using International Headache Society Criteria. In addition, the studies have not included 
brain imaging (if stroke were shown, for example, the stroke would explain the association with aPL). We 
do not recommend treatment with anticoagulants if migraine is the unique symptom. Well-designed 
randomized controlled trials are urgently needed to verify the possible association between refractory 
migraine or migraine like and PAPS. The final evaluation of these efforts was GRADE very low for the 
body of evidence. 
The outcome of this analysis does not support the assumption that migraine and APS are causally 
associated. We strongly recommend that further studies applying clinical and laboratory diagnostic 
criteria both for headache, brain imaging and for APS are needed in order to study a possible association. 
It is important to emphasize that additional work is also required to assess whether antithrombotic or 
other drugs targeting aPL may be advantageous in patient without a history of thrombosis. 
4.7. Chorea, seizures and longitudinal myelitis 
Specific question (chorea, longitudinal myelitis and seizures): “In patients with APS (P), is chorea (I) 
associated with APS diagnose, leading to earlier and most adequate treatment intervention to 
prevent thrombotic events or other neurologic complications (O)”? 
4.7.1. Patient-important outcomes 
A spectrum of neuropsychiatric manifestations, including stroke and TIA are accepted as “thrombotic”, 
but other inflammatory manifestations may occur in the neurologic system. Many other neuropsychiatric 
manifestations, including chronic headache, cognitive dysfunction, psychosis, depression and multiple 
sclerosis-like-illness, have also been reported with aPL positivity. 
4.7.2. Findings 
For the purpose of this paper, the experts considered chorea, longitudinal myelitis and seizures separately. 
The late Ronald Asherson et al. first considered the association between chorea and SLE in 1987, when 
they described a case series. They reported twelve patients with chorea from a population of 500 patients 
with SLE and “lupus-like” disease, including a clinical review, time relationship of the chorea to the 
systemic illness and other neurologic manifestations. Chorea appeared early in the course in most 
patients, but the development of cerebral infarctions or TIAs occurred subsequently in seven out of nine 
patients with aPL [61]. Some questions derived from these observations and guided subsequent studies. 
Chorea is a rare manifestation of APS. The Euro-Phospholipid Project has estimated that the prevalence 
of chorea in APS is of 1.3%. Chorea has been described in association with primary APS in a number of 
patients, published as case reports and some case series [62]. Orzechowski et al. [63] and Reiner et 
al. [64] also observed association between APS and chorea. 
The association of seizures with aPL antibodies in SLE or non-SLE has been widely studied, with 
conflicting results. Verrot et al. [65]; Cimaz et al. [66]; Peltola et al. [67]; and the case–control series of 
Liimatainen et al. [68] described seizures in non-SLE patients with increased aPL. On the other hand, 
seizures in SLE patients were described with positive results by Herranz et al. [69]; Mackworth-Young 
and Hughes [70], Toubi et al. [71]; Liou et al. [72]; Kavassa et al. [73]; Mok et al. [74]; Sanna et al. [75]; 
Appenzeller et al. [76]and Mikdashi and Handwerger [77]. Sachse et al. [78] and Formiga et 
al. [79] described negative associations. Additionally, if SLE patients with strokes are excluded, there is 
no association of seizure with lupus anticoagulant (Table 1). 
Longitudinal myelitis is an acute inflammatory process that affects a longitudinal segment of the spinal 
cord. D'Cruz et al. reported 15 patients in whom longitudinal myelitis was the initial manifestation of SLE 
or of lupus-like disease [80]. Of those patients, 73% tested positive for aPL, which provides further 
evidence of a strong correlation between longitudinal myelitis and aPL positivity. The pathogenic 
mechanism seems to involve a direct interaction between aPL and spinal cord phospholipids rather than a 
thrombotic process leading to ischaemia, although no strong correlation has been made between these 
manifestations and APS. Birnbaum et al. [81] described distinct subtypes of myelitis in systemic lupus 
erythematosus. Eleven patients presented with signs of gray matter dysfunction (i.e., flaccidity and 
hyporeflexia), whereas 11 patients presented with signs of white matter dysfunction (i.e., spasticity and 
hyperreflexia). Patients with gray matter dysfunction were more likely to have irreversible paraplegia 
(p < 0.01), despite presenting with a monophasic versus polyphasic course (p = 0.01), higher levels of 
SLE activity (mean SLE Disease Activity Index 9.8 versus 2.0; p = 0.01), and a cerebrospinal fluid 
profile indistinguishable from bacterial meningitis. Prior to irreversible paraplegia, these patients 
presented with prodromes of fever and urinary retention, but were misdiagnosed by physicians of 
different specialties as having urinary tract infections. Patients with white matter dysfunction were more 
likely to meet criteria for neuromyelitis optica (p = 0.04) and were also more likely to have aPL (lupus 
anticoagulant) (p = 0.01). These findings indicate that SLE myelitis encompasses two distinct and 
previously unrecognized syndromes that can be distinguished clinically by gray matter versus white 
matter findings. Recognition of fever and urinary retention as prodromes of irreversible paraplegia may 
allow earlier diagnosis and treatment in SLE patients presenting with gray matter findings. 
4.7.3. Overall quality of evidence and recommendations 
There are neurologic, cardiac and hematologic manifestations of aPL. The mechanism is inflammation, as 
they respond to corticosteroids. We should stop calling them “non-criteria” and re-think what APS really 
means. All future studies of seizure with aPL must include brain imaging and adjust for the occurrence of 
stroke as the cause of seizure. 
4.8. The so-called seronegative APS (SN-APS) 
Specific question 1: In patients with clinical features suggestive of APS which are persistently negative 
for the routinely aPL (aCL, anti-b2GPI, and LA) what is the advantage to classify them as seronegative 
APS (SN-APS)? Does this lead to earlier and most adequate treatment intervention to prevent further 
thrombotic events? 
PO — P-APS; O — thrombotic events. 
Specific question 2: In real clinical practice (P), how often are the discrepancies between aPL detection 
and clinical APS expression (O)? 
Patient-important outcome: peculiar thrombotic events. 
Surrogate: so-called seronegative APS (SN-APS). 
Preliminary relative importance: critical for decision-making. 
4.8.1. Patient-important outcomes 
The notion of a clinical syndrome, where classical clinical manifestations (Sapporo/Sydney criteria) allied 
to some of the most commonly associated features (non-criteria manifestations) could suggest a 
hypercoagulability state including APS, even though none of the aPL antibodies of the classification 
criteria is found, seems plausible[82] and [83]. This notion was raised based on clinical observations, and 
first published in 2003 by Hughes and Khamashta. Therefore, the term ‘seronegative APS’ (SN-APS) has 
been coined to include these patients with clinical features suggestive of APS who are persistently 
negative for aPL and other thrombophilias [84]. The importance of this observation is due to the fact that 
these patients will require proper counseling (to reduce the thrombotic risk) and sometimes also 
treatment, because they are prone to recurrent thromboses and even catastrophic events. The other 
relevant dimension of this debate is related to the factors that can suggest the presence of SN-APS to the 
characteristics of endothelial molecules specifically recognized by serum autoantibodies to define SN-
APS[85]. 
There was a controversy among the task force members, which discussed that despite the robust 
association between autoantibodies and APS, some patients remain persistently negative for disease 
specific autoantibodies. On the other hand, though the prevalence of seronegative autoimmune diseases is 
low, they may represent a practical problem because they are often difficult cases and should not remain 
untreated. When there is a clinical picture suggestive of APS, and transient negativity due to recent 
thrombosis and antibody consumption, as well as other causes of thrombosis are excluded, it is important 
to consider a clinical diagnostic of APS. Therefore, it was proposed for these cases the so-called term 
“seronegative APS (SN-APS)” when the classical tests are not detected, but there may be isolated IgA 
reactivity or to other test (anti-PS/PT, anti-D1, anti-annexin V, aCL/vimentin or others that were 
discussed by the laboratory Task Force) that is not included in the criteria, and not yet standardized and 
widely available [86], [87] and [88]. 
The dimensions on the existence of SN-APS concepts may be summarized on clinical observations; 
challenges on prevalence studies and challenges on laboratory studies. The importance of this debate is 
directly linked to the consequences for patients, as the decisions required will — or not — be influenced 
by it. Taking these points into account, this outcome is considered as important and very critical for 
decision making, as the consequences of a misdiagnosis can be bound to serious and life threatening 
conditions. 
4.8.2. Findings 
There were seven studies included on this analysis: two case reports, one case–control, three cohort 
studies, and one non-systematic literature review. The two case-reports are presented here in order to 
provoke the discussion about the consequence of this diagnosis for the clinical practice, but were not 
included in the analyses. As patient important outcomes are categorized by how critical is the 
consequence of the misdiagnosis — and consequently, the mistreatment for the patient, these cases can 
contribute for the constructs of the questions. Also, we included a literature review published by Cervera 
et al. that present the arguments for and against the existence of SN-APS [89]. 
In this cited literature review, the authors discussed that in favor of this are the fact that new emerging 
aPL assays could improve our ability in diagnosing APS. Transient or false negative aPL assay and other 
genetic or acquired pro-thrombotic conditions have to be considered and can further complicate this issue. 
On the other hand, one of the most critical issues is that most laboratories test only IgG and IgM aCL 
(few may be able to test for IgA) and LA, and only a few of them test anti-b2GPI (primarily IgG isotype). 
Furthermore, the currently available assays cannot detect all potential aPL, and the new specificities, 
recently identified, are tested in only a few research laboratories. Another important issue is that transient 
aPL seronegativity which may be due to different causes, such as nephrotic syndrome, treatment with 
corticosteroids, immunosuppressants, or antibody consumption during thrombotic event may take a 
longer follow-up and persistent re-testing for identification. 
There is only one paper comparing SNAPS and seropositive APS [90]. The authors retrospectively 
assessed clinical manifestations of APS in 154 patients: 87 patients with seropositive APS and 67 patients 
with thrombosis and/or pregnancy morbidity persistently negative for aPL and presenting with at least 
two additional non-criteria manifestations of APS (the so-called ‘seronegative APS’, SN-APS). The 
results showed no significant differences in the frequency of thrombotic events or obstetric morbidity in 
patients with SN-APS versus patients with seropositive APS: deep vein thrombosis (31.4% vs. 31.0%), 
pulmonary embolism (23.8% vs. 28.7%), stroke (14.9% vs. 17.2%), transient ischaemic attack (11.9% vs. 
10.3%), early spontaneous abortions (67.1% vs. 52.1%), stillbirths (62.5% vs. 59.4%), prematurity 
(28.1% vs. 21.7%) or pre-eclampsia (28.1% vs. 23.1%). Based on this, the authors suggest that clinical 
management in patients with APS should not be based only on the presence of conventional aPL. 
The understanding of the prevalence of aPL in patients with SLE in addition to the knowledge of the 
association with thrombosis, association with non-thrombotic disease manifestations, and lack of 
association with atherosclerosis were the issues explored by the review of Hopkins' Lupus Cohort [91]. In 
spite of its indirectness for this discussion here (it analyzed SLE patients), these findings can contribute to 
go beyond this debate. The aPL detection as common in patients in the Hopkins' Lupus Cohort: 47% have 
aCL, 32.5% anti-b2GPI and 26% LA (by dRVVT confirmatory testing) is an important finding to this 
specific debate; and the fact that aPL were not associated with atherosclerosis. 
In addition of this study, anti-prothrombin antibodies (aPT) have been reported as the sole antibodies 
detected in a few patients with SLE and a history of thrombosis but persistently negative for aCL or 
LA [92]. Also, it has been shown that antibodies directed to the lyso (bis) phosphatidic acid (aLBPA) may 
represent a marker of APS showing similar sensitivity and specificity compared to anti-b2GPI. In 
addition, aLBPA are associated strongly with the presence of LA. Conti investigated the clinical 
usefulness of thin-layer chromatography (TLC) immunostaining in detecting serum aPL in patients 
presenting clinical features of SN-APS. Sera from 36 patients with SN-APS, 19 patients with APS, 18 
with SLE, 20 anti-hepatitis C virus-positive subjects and 32 healthy controls were examined for aPL 
using TLC immunostaining [93]. 
The outcomes assessed on this cohort were venous and/or arterial thrombosis and pregnancy morbidity, as 
stated in the classification criteria for definite APS. TLC immunostaining showed aPL in 58.3% of SN-
APS patients: aCL in 47.2%, anti-lyso (bis) phosphatidic acid in 41.7% and anti-
phosphatidylethanolamine in 30.5%. Six of 36 patients showed anti-annexin II. Also, they found a 
statistically significant correlation was found between vascular thrombosis (arterial and/or venous) and 
pregnancy morbidity in SN-APS (p < 0.0001); and a statistically significant correlation was found among 
aCL, aLBPA and aPE positivity (p < 0.02). The most relevant finding of this study is that TLC 
immunostaining could potentially identify the presence of aPL in patients with clinical features suggestive 
of APS not ascertained by traditional tests for aPL, and such identification could have a major impact on 
the prognosis and therapeutic approach. 
4.8.3. Overall quality of evidence and recommendations 
The existence of SN-APS is debated among the task force members, as the concept of the “so-called” 
Seronegative APS is still hotly debated. Even though, some considered that it is important to be evaluated 
and that it's prognostic significance must be elucidated. This scenario could represent a trade-off between 
the low quality of evidence (GRADE low) and a critical for decision-making outcome. 
5. Discussion 
A series of clinical features, that are not included in the classification criteria, but are recognized to be 
related to APS have been named non-classical or non-criteria clinical manifestations. An International 
Task Force reviewed those that were considered more clinically relevant, in addition to SN-APS, that 
although it is not consensus among the task force members, some considered it important to be 
investigated. We used the GRADE system to evaluate the medical literature on the relevance of 
considering the inclusion of each feature as part of a revised classification criterion, which will aid to 
recognize the broader spectrum of the clinical picture of APS. These clinical characteristics are not 
exclusively related to pathogenic events clearly involving thromboses, but occur also when thrombosis is 
not evident. Their relationship with aPL and the classical features of APS urges us to give these features 
their proper value in diagnostic work-up, in terms of defining prognostic and morbidity correlations and 
optimally provide diagnostic investigation, as well as, treatment recommendation when appropriate in 
order to improve patient outcome. 
To start making recommendations regarding APS criteria, the GRADE system considers the balance of 
patient-important outcomes, the overall quality of the evidence for each outcome, the uncertainty about 
values and preferences associated with the diagnostic strategies and the presumed patient-important 
outcomes, and cost. We analyzed the outcomes presented by the APS experts that were discussed during 
the task force. Then, we categorized their importance to patient care, and analyzed the overall quality of 
evidence. Finally, we presented the strength to consider each one as part of APS diagnostic criteria 
(Table 2). 
Analyzing SVT, there is a low overall quality of evidence to support the suggestion that SVT is due to 
aPL/APS, unless there are other features of APS. 
Thrombocytopenia is critical for decision-making. Once the most common causes are ruled out, aPL 
should be checked even in the absence of other features that are characteristic of APS. The overall quality 
of evidence for this finding was low. In general, aPL related thrombocytopenia is mild or moderate and 
the risk of bleeding is minimal even with very low counts. Data in the literature indicate that thrombosis 
risk is increased in these patients. 
Kidney failure or deaths due to kidney failure are the worst consequences of APS nephropathy. These are 
the patient-important outcome here and they are critical for decision-making. Based on them, and the 
moderate quality of the overall evidence, there is strong support to have the diagnosis confirmed by 
histopathology, taking into consideration that TMA is a surrogate for the patient-important outcome. 
Patient-important outcomes linked to heart valve disease related to aPL were categorized as very critical 
for decision making. Taking this, together with the moderate quality of the body of the evidence, there is 
moderate support to recommend its inclusion as part of APS classification criteria. 
Livedo reticularis can be associated with the occurrence of thrombosis and this outcome was defined as 
important but not critical for decision-making. There is a suggestion, with moderate quality of evidence 
that it can be included as part of diagnostic criteria. In the same way, migraine can be associated with 
thrombotic events, but this outcome was categorized as low importance for decision-making. Chorea, 
myelitis and seizures were analyzed separately in this task force. Their consequences for decision-making 
were categorized as very critical for decision making, which support, based on the overall quality of 
evidence, that chorea and longitudinal myelitis should be included as part of APS criteria but not seizures. 
Regarding SN-APS, the consequences for decision-making, are categorized as very critical for decision-
making. Despite this, the overall quality of evidence was low, as they included editorials, non-systematic 
review, and case reports, which downgrade the body of evidence. Therefore, considering the trade-off 
between misdiagnosis and the risk of future events, it is strongly recommended to conduct further studies 
to determine its real significance. 
6. Conclusion 
The purpose of this task force was to critically analyze the so-called non-criteria manifestations of APS to 
support their inclusion as APS classification criteria. Classification criteria are important for including 
homogeneous groups of patients in observational as well as in therapeutic studies. The case has been 
made for including thrombocytopenia, renal microangiopathy, heart valve disease and two neurological 
manifestations (chorea and longitudinal myelitis) as classification criteria. However such a decision 
should be carefully balanced because a change of classification criteria will lead to consider different 
subsets of patients as APS patients. Thus a consensus not only of the authors of the present paper but of 
all experts in the field is needed. Such an effort is currently underway for the next antiphospholipid 
meeting in Istanbul and the present review will be a basis for classification revision. 
Take-home messages 
• The purpose of this task force was to critically analyze the so-called non-criteria manifestations of APS 
to support their inclusion as APS classification criteria. 
• Using GRADE system, we found that overall quality of evidence was very low for migraine and 
seizures,;low for superficial venous thrombosis, thrombocytopenia, chorea, longitudinal myelitis and the 
so-called seronegative APS, and moderate for APS nephropathy, heart valve lesions and livedo 
reticularis. 
• A critical redefinition of an APS gold standard will be the next steps and it can include data from the 
APS ACTION registry that will include not only current APS patients but also those with 
antiphospholipid antibodies not meeting current classification criteria. 
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Table 1. 
Association of seizures in with lupus anticoagulant in SLE: Hopkins Lupus Cohort. 
Seizures LAC positive (N = 591) LAC negative (N = 1615) p-Value 
13% 8.5% 0.0017 
aCL positive (n = 591) aCL negative (N = 1615) p-Value 
9.4% 10.2% 0.5658 
Seizures without stroke LA positive (N = 493) LA negative (N = 1515) p-Value 
9.4% 7.7% 0.22 
aCL positive (N = 591) aCL negative (N = 1615) p-Value 
7.4% 8.8% 0.25 
 
 
 
 
 
 
 
 
 
Table 2. Result of the complete critical analysis. 
Criteria  PIOa Relevance category of 
PIO 
Overall 
GRADE 
analysis 
Recommendation b and c 
Superficial venous 
thrombosis 
 Recurrent thrombotic events, 
including life threatening 
event 
Important but not 
critical for decision-
making 
Low Suggestion to be 
included 
Thrombocytopenia  Recurrent thrombotic events, 
including life threatening 
event 
Critical for decision 
making 
Low Recommended to be 
included 
APS Nephropathy  Kidney failure, death by 
kidney failure 
Critical for decision 
making 
Moderate Strongly recommended 
to be included 
Valve heart lesions  Heart failure, valve 
replacement, death by heart 
failure 
Critical for decision 
making 
Moderate Strongly recommended 
to be included 
Livedo reticularis  Recurrent thrombotic events, 
including life threatening 
event 
Important but not 
critical for decision-
making 
Moderate Recommended to be 
included 
Neurological 
manifestations 
Migraine Recurrent thrombotic events, 
including life threatening 
event 
Important but not 
critical for decision-
making 
Very low Not recommended to be 
included 
Chorea Stroke, neurological arterial 
and venous thrombosis 
Critical for decision 
making 
Low Recommended to be 
included 
Seizures Stroke, neurological arterial 
and venous thrombosis 
Critical for decision 
making 
Very low Not recommended to be 
included 
Longitudinal 
myelitis 
Stroke, neurological arterial 
and venous thrombosis 
Critical for decision 
making 
Low Recommended to be 
included 
Seronegative APS  Recurrent thrombotic events, 
including life threatening 
event 
Critical for decision 
making 
Low Recommended to be 
included 
 
